

Resource Summary Report

Generated by [RRID](#) on Aug 11, 2026

[timeROC](#)

RRID:SCR_026444

Type: Tool

Proper Citation

timeROC (RRID:SCR_026444)

Resource Information

URL: <https://CRAN.R-project.org/package=timeROC>

Proper Citation: timeROC (RRID:SCR_026444)

Description: Software R package for estimation of time-dependent ROC curve and area under time dependent ROC curve in the presence of censored data, with or without competing risks. Confidence intervals of AUCs and tests for comparing AUCs of two rival markers measured on the same subjects can be computed, using the iid-representation of the AUC estimator.

Resource Type: software toolkit, software resource

Keywords: estimation of time-dependent ROC curve and area, presence of censored data,

Availability: Free, Available for download, Freely available

Resource Name: timeROC

Resource ID: SCR_026444

License: GNU GPL v3

Record Creation Time: 20250221T060325+0000

Record Last Update: 20260810T040907+0000

Ratings and Alerts

No rating or validation information has been found for timeROC.

No alerts have been found for timeROC.

Data and Source Information

Usage and Citation Metrics

We found 19 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Xun Y, et al. (2026) Integrative analysis of a novel snoRNA-based prognostic signature in patients with breast cancer. *Frontiers in oncology*, 16, 1779697.

Luo T, et al. (2026) Integrative multi-omics and network analysis identify potential targets of Chaihu Shugan Xiaozheng Formula in breast cancer. *Translational oncology*, 70, 102829.

Li M, et al. (2026) STOML2 promotes hepatocellular carcinoma cell proliferation, invasion and migration by activating the PI3K/AKT signaling pathway (Review). *Oncology letters*, 31(4), 135.

Funk AM, et al. (2026) A Urinary Three-Metabolite Signature Enables Noninvasive Identification of Patients with High-Risk Ovarian Cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(14), 2968.

Liu Y, et al. (2025) A prognostic signature for hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. *Scientific reports*, 15(1), 26617.

Lin YW, et al. (2025) Comprehensive analysis based on the ubiquitination- and deubiquitylation-related genes reveals the function of NEURL3 in esophageal squamous cell carcinoma. *Frontiers in immunology*, 16, 1632090.

Huang C, et al. (2025) Prediction of recurrence after resection in hepatocellular carcinoma via whole liver deep learning on preoperative contrast-enhanced CT. *Scientific reports*, 15(1), 42975.

Zhao Z, et al. (2025) Immune infiltration and stromal heterogeneity in pancreatic cancer: A prognostic model guiding immunotherapy response. *Oncology letters*, 30(4), 465.

Wang C, et al. (2025) ANTP-SmacN7 enhances radiosensitivity in TPC-1 cells through XIAP-mediated activation of apoptotic protein. *Scientific reports*, 15(1), 25779.

Zhang S, et al. (2025) Immunosequencing identifies signatures of T cell responses for early detection of nasopharyngeal carcinoma. *Cancer cell*, 43(8), 1423.

Yang J, et al. (2024) Prognostic impact of MALs and potential immunotherapy targets in uveal melanoma. *Pediatric discovery*, 2(3), e54.

Liu X, et al. (2024) CFLAR: A novel diagnostic and prognostic biomarker in soft tissue sarcoma, which positively modulates the immune response in the tumor microenvironment. *Oncology letters*, 27(4), 151.

Zheng X, et al. (2023) Identification of a seven-lncRNAs panel that serves as a prognosis predictor and contributes to the malignant progression of laryngeal squamous cell carcinoma. *Frontiers in oncology*, 13, 1106249.

Shi Q, et al. (2023) A novel prognostic model for hepatocellular carcinoma based on pyruvate metabolism-related genes. *Scientific reports*, 13(1), 9780.

Xu R, et al. (2022) Identification of Tumor Antigens and Immune Subtypes in Lung Adenocarcinoma for mRNA Vaccine Development. *Frontiers in cell and developmental biology*, 10, 815596.

Li RQ, et al. (2022) Identification of tumor antigens and immune subtypes in breast cancer for mRNA vaccine development. *Frontiers in oncology*, 12, 973712.

Huang L, et al. (2020) EFEMP2 indicates assembly of M0 macrophage and more malignant phenotypes of glioma. *Aging*, 12(9), 8397.

Xie P, et al. (2019) Development of an Immune-Related Prognostic Signature in Breast Cancer. *Frontiers in genetics*, 10, 1390.

Jiang Y, et al. (2018) Construction of a set of novel and robust gene expression signatures predicting prostate cancer recurrence. *Molecular oncology*, 12(9), 1559.